Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Effect of Meal Frequency on Diet Self-Efficacy and Perceived Stress in Women With Weight Cycling

8 de maio de 2026 atualizado por: İlknur Gökçe YILDIRIM=, Ankara Medipol University

Effect of a Diet Intervention With Different Meal Frequencies on Diet Self-Efficacy and Perceived Stress in Women With Weight Cycling: A Randomized Controlled Trial

The World Health Organization (WHO) defines obesity as abnormal or excessive fat accumulation in the body that may adversely affect health. In 2022, 1 in 8 people worldwide lived with obesity, while the adult obesity rate has more than doubled since 1990, and the adolescent obesity rate has quadrupled.

Obesity is a risk factor for noncommunicable diseases such as type 2 diabetes, hypertension, cardiovascular diseases, cancer, and sleep apnea, and is associated with an increased risk of death. The treatment of obesity-related comorbidities, along with indirect costs resulting from lost productivity and premature death, contributes to the economic burden caused by obesity. Therefore, effective management of obesity is of critical importance for improving overall health outcomes and reducing the burden on healthcare systems. It has been demonstrated that a 5% reduction in body weight in individuals diagnosed with obesity can improve health outcomes, and this value has been established as a target standard for weight loss interventions. However, while dietary interventions can achieve clinically meaningful weight loss, weight regain is common due to a combination of low adherence to dietary strategies and compensatory physiological mechanisms that influence weight regain. Consequently, individuals may find themselves in a "weight cycle," losing weight and then regaining it. Weight maintenance is defined as intentional weight loss followed by the preservation of that loss for at least six months. It has been noted that the weight cycle complicates this process.

The weight cycle defined as repeated periods of intentional weight loss followed by regain is considered a common yet poorly understood factor among obese individuals. The weight cycle is viewed as one of the major challenges in clinical obesity care. For this reason, it is emphasized that strategies aimed at preventing weight cycling or promoting weight maintenance have gained importance. Additionally, attention is drawn to psychological factors in eating behavior, with particular emphasis on the individual's self-confidence and stress levels being crucial for sustaining healthy eating behaviors.

Individuals experiencing weight cycling often face challenges with diet adherence, sustainability, and stress management. Meal frequency strategies applied to these individuals can influence not only weight loss but also diet adherence and the psychological experience of the dietary process. Given the rise in obesity and obesity-related disorders, understanding the relationship between stress, self-efficacy, and food choice in young adulthood may offer insights into preventing adverse health outcomes in later life stemming from poor dietary habits. An appropriate meal schedule can help an individual adapt better to the diet and manage the process with less stress; thereby facilitating weight maintenance success and making healthy eating a lifestyle. However, in the treatment of obesity, data regarding different meal frequency approaches in dietary interventions remain controversial.

The aim of this study is to examine the factors influencing the sustainability of the diet and the long-term maintenance of weight loss in individuals experiencing weight cycling. In this context, the effects of different meal frequencies on this process were evaluated; the study addressed not only physical outcomes but also psychological factors such as how individuals felt during the dietary process, their stress levels, and their self-confidence. Thus, the aim was to present a more comprehensive perspective by examining the relationship between meal frequency and weight management from both physiological and psychological dimensions.

Visão geral do estudo

Descrição detalhada

The study was conducted on women aged 25-55 who voluntarily applied to a dietary counseling office, met the inclusion criteria, had a BMI between 25 and 35 kg/m², and experienced weight fluctuations. In the analysis conducted to determine the sample size, the effect size was f = 0.204, the Type I error level was α = 0.05, the test power (1-β) was 0.95, and measurements were taken at 6 time points (0, 2, 4, 6, 8 Weeks and 6 months after the intervention ended), inter-measurement correlation r = 0.50, and the non-sphericity correction ε = 1. Under these conditions, the required total sample size was determined to be 41; considering the anticipated 20% participant attrition during the study, it was determined that at least 49 participants were needed, and to obtain more accurate data, it was planned to include at least 52 participants; the study was completed with a total of 59 participants. The intervention phase of the study lasted 8 weeks for each participant. During the intervention period, face-to-face interviews were conducted every 2 weeks, and all measurements within the scope of the study were repeated. Following the completion of the 8-week intervention, no further intervention or follow-up was conducted, and participants' ability to maintain their weight loss was assessed via a single follow-up measurement 6 months later. In accordance with the recommendations, a weight-loss diet was planned and implemented for each participant, reducing daily energy intake by 500-700 kcal to facilitate a weight loss of 0.5-1.0 kg per week; A weight-loss diet appropriate for the women's age and energy and nutrient requirements was planned, and two groups were formed using a simple randomization method. Group 1 followed a meal plan consisting of 3 main meals, while Group 2 followed a meal plan consisting of 3 main meals and 3 snacks. Written and verbal informed consent was obtained from all participants via the "Informed Consent Form." At the beginning of our study, a general information form, a three-day food consumption record, the International Physical Activity Questionnaire Short Form (IPAQ SHORT FORM), the Perceived Stress Scale (PSS), the Dietary Self-Efficacy Scale (DESS), and the General Well-Being Scale Short Form (GWBS-SF) were used. At the 8th week, when the intervention ended, and at the 6-month follow-up, the Perceived Stress Scale (PSS), Dietary Self-Efficacy Scale (DESS), and General Well-Being Scale Short Form (GWBS-SF) were repeated. Anthropometric measurements and body composition analyses conducted as part of the study (body weight, height, BMI, waist-to-height ratio, waist circumference, hip circumference, neck circumference, waist-to-height ratio waist-to-hip ratio, total body fat (kg and %), lean body mass (kg and %), body water (L ), basal metabolic rate (kcal)) were performed at weeks 0, 2, 4, 6, and 8, as well as 6 months after the intervention ended. Anthropometric measurements were taken using standard measurement techniques, while body composition analyses were performed using the INBODY 270 device. Anthropometric indices (Lipid Accumulation Product Index - LAP, Visceral Adiposity Index - VAI, Conicity Index - CI, Body Shape Index - ABSI, Abdominal Volume Index - AVI, Body Adiposity Index - BAI, Body Roundness Index - BRI, Anthropometric Risk Index - ARI) calculated using validated formulas based on anthropometric measurements and relevant biochemical parameters. Participants' biochemical test results were used to develop individualized dietary plans and to observe changes in biochemical findings during the weight loss process. No new blood tests were requested from the participants in this study. The biochemical data used in the study (fasting blood glucose, triglycerides, total cholesterol, HDL-C, LDL-C, TSH, ALT, AST, HbA1c) were obtained from laboratory results recorded in the participants' health records and dating back to the past 3 months. Note: This trial was retrospectively registered. Data collection was completed prior to registration in ClinicalTrials.gov.

Tipo de estudo

Intervencional

Inscrição (Real)

72

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Altındağ
      • Ankara, Altındağ, Turquia (Türkiye)
        • Ankara Medipol University

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto

Aceita Voluntários Saudáveis

Não

Descrição

Inclusion Criteria:

  • Female participants aged 25-55 years
  • Body mass index (BMI) between 25 and 35 kg/m²
  • having a history of weight fluctuations
  • Willingness to participate and provide informed consent

Exclusion Criteria:

  • Presence of cardiovascular disease
  • Chronic kidney disease
  • Hypertension
  • Diagnosis of Type 1 or Type 2 diabetes mellitus
  • Pregnancy or breastfeeding
  • Use of any medication or dietary supplement for weight loss or fat reduction
  • Engagement in intense physical activity
  • No having a history of weight fluctuations
  • Menopausal status
  • Failure to attend scheduled follow-up visits
  • Non-adherence to the intervention protocol for three consecutive days

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: 3 Meal Group
Participants followed a weight-loss diet consisting of 3 main meals per day.
A personalised weight-loss diet that reduces daily calorie intake by 500-700 kcal. Group 1 followed the diet for 8 weeks, consisting of 3 main meals a day.
Experimental: 6 Meal Group
Participants followed a weight-loss diet consisting of 3 main meals and 3 snacks per day.
A personalised weight-loss diet that reduces daily calorie intake by 500-700 kcal. Group 1 followed the diet for 8 weeks, consisting of 3 main meals and 3 snacks per day.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Body weight (kg)
Prazo: Baseline, Weeks 2, 4, 6, and 8, and 6 months post-intervention
Body weight measured using a calibrated digital scale
Baseline, Weeks 2, 4, 6, and 8, and 6 months post-intervention
Body mass index (kg/m²)
Prazo: Baseline, Weeks 2, 4, 6, and 8, and 6 months post-intervention
Calculated as body weight in kilograms divided by height in metres squared
Baseline, Weeks 2, 4, 6, and 8, and 6 months post-intervention
Height (cm)
Prazo: Baseline, Weeks 2, 4, 6, and 8, and 6 months post-intervention
Height measured using a stadiometer with participants standing upright, feet together, in Frankfurt plane position.
Baseline, Weeks 2, 4, 6, and 8, and 6 months post-intervention
Waist circumference (cm)
Prazo: Baseline, Weeks 2, 4, 6, and 8, and 6 months post-intervention
Waist circumference was measured using a non-stretch tape measure along the midline between the lowest rib and the iliac crest, with the individual standing with their feet together and arms at their sides in a relaxed position.
Baseline, Weeks 2, 4, 6, and 8, and 6 months post-intervention
Hip circumference (cm)
Prazo: Baseline, Weeks 2, 4, 6, and 8, and 6 months post-intervention
Hip circumference was measured using a non-stretchable tape measure across the widest part of the hips, with the individual standing upright, feet together and arms at their sides
Baseline, Weeks 2, 4, 6, and 8, and 6 months post-intervention
Neck circumference (cm)
Prazo: Baseline, Weeks 2, 4, 6, and 8, and 6 months post-intervention
During neck circumference measurements, participants were positioned upright with their arms at their sides and their feet together. The measurements were taken by the researcher, who stood opposite the participant, using a non-stretchable tape measure around the neck near the shoulder.
Baseline, Weeks 2, 4, 6, and 8, and 6 months post-intervention
waist-to-height ratio
Prazo: Baseline, Weeks 2, 4, 6, and 8, and 6 months post-intervention
Waist-to-height ratio calculated by dividing waist circumference (cm) by height (cm).
Baseline, Weeks 2, 4, 6, and 8, and 6 months post-intervention
waist-to-hip ratio
Prazo: Baseline, Weeks 2, 4, 6, and 8, and 6 months post-intervention
Waist-to-hip ratio calculated by dividing waist circumference (cm) by hip circumference (cm).
Baseline, Weeks 2, 4, 6, and 8, and 6 months post-intervention
basal metabolic rate (kcal)
Prazo: Baseline, Weeks 2, 4, 6, and 8, and 6 months post-intervention
The measurements were taken using bioelectrical impedance analysis (BIA) with the INBODY 270 device.
Baseline, Weeks 2, 4, 6, and 8, and 6 months post-intervention
Body Fat mass (kg)
Prazo: Baseline, Weeks 2, 4, 6, and 8, and 6 months post-intervention
The measurements were taken using bioelectrical impedance analysis (BIA) with the INBODY 270 device.
Baseline, Weeks 2, 4, 6, and 8, and 6 months post-intervention
Lean body mass (kg)
Prazo: Baseline, Weeks 2, 4, 6, and 8, and 6 months post-intervention
The measurements were taken using bioelectrical impedance analysis (BIA) with the INBODY 270 device.
Baseline, Weeks 2, 4, 6, and 8, and 6 months post-intervention
Percentage of lean body mass(%)
Prazo: Baseline, Weeks 2, 4, 6, and 8, and 6 months post-intervention
The measurements were taken using bioelectrical impedance analysis (BIA) with the INBODY 270 device.
Baseline, Weeks 2, 4, 6, and 8, and 6 months post-intervention
Body fat percentage (%)
Prazo: Baseline, Weeks 2, 4, 6, and 8, and 6 months post-intervention
The measurements were taken using bioelectrical impedance analysis (BIA) with the INBODY 270 device.
Baseline, Weeks 2, 4, 6, and 8, and 6 months post-intervention
Total body water (L)
Prazo: Baseline, Weeks 2, 4, 6, and 8, and 6 months post-intervention
The measurements were taken using bioelectrical impedance analysis (BIA) with the INBODY 270 device.
Baseline, Weeks 2, 4, 6, and 8, and 6 months post-intervention
Lipid accumulation product index-LAP
Prazo: Baseline, Week 8 and 6 months post-intervention
Calculated using validated formulas based on anthropometric measurements and relevant biochemical parameters (waist circumference(cm) and triglycerides (mmol/L))
Baseline, Week 8 and 6 months post-intervention
Visceral adiposity index-VAI
Prazo: Baseline, Week 8 and 6 months post-intervention
Calculated using validated formulas based on anthropometric measurements and relevant biochemical parameters (waist circumference (cm), body mass index(kg/m²),HDL-C (mmol/L) and triglycerides (mmol/L)).
Baseline, Week 8 and 6 months post-intervention
Conicity index - CI
Prazo: Baseline, Week 8 and 6 months post-intervention
Calculated using validated formulas based on anthropometric measurements and relevant biochemical parameters (waist circumference (m),Body weight (kg), Height (m) )
Baseline, Week 8 and 6 months post-intervention
A body shape index-ABSI
Prazo: Baseline, Week 8 and 6 months post-intervention
Calculated using validated formulas based on anthropometric measurements and relevant biochemical parameters (waist circumference (m), BMI(kg/m²) and heigh(m))
Baseline, Week 8 and 6 months post-intervention
Abdominal volume index-AVI
Prazo: Baseline, Week 8 and 6 months post-intervention
Calculated using validated formulas based on anthropometric measurements and relevant biochemical parameters (waist circumference (cm), hip circumference (cm)).
Baseline, Week 8 and 6 months post-intervention
Body adiposity index-BAI
Prazo: Baseline, Week 8 and 6 months post-intervention
Calculated using validated formulas based on anthropometric measurements and relevant biochemical parameters (Hip circumference (cm), Height (m)).
Baseline, Week 8 and 6 months post-intervention
Body roundness index-BRI
Prazo: Baseline, Week 8 and 6 months post-intervention
Calculated using validated formulas based on anthropometric measurements and relevant biochemical parameters (Waist circumference (m), Height (m)).
Baseline, Week 8 and 6 months post-intervention
Anthropometric risk index-ARI
Prazo: Baseline, Week 8 and 6 months post-intervention
Anthropometric Risk Score (ARS) is a composite score calculated by scoring each anthropometric parameter (BMI, waist circumference, waist-to-hip ratio, and waist-to-height ratio) based on established reference cutoff values and summing the individual scores.
Baseline, Week 8 and 6 months post-intervention
Fasting blood glucose (mg/dL)
Prazo: Baseline, Week 8 and 6 months post-intervention
No additional blood samples were collected from participants. Biochemical data were obtained from existing health records, reflecting results from the previous 3 months, measured after a minimum 8-hour fasting period using standard laboratory methods.
Baseline, Week 8 and 6 months post-intervention
Triglycerides (mg/dL)
Prazo: Baseline, Week 8 and 6 months post-intervention
No additional blood samples were collected from participants. Biochemical data were obtained from existing health records, reflecting results from the previous 3 months, measured after a minimum 8-hour fasting period using standard laboratory methods.
Baseline, Week 8 and 6 months post-intervention
Total cholesterol (mg/dL)
Prazo: Baseline, Week 8 and 6 months post-intervention
No additional blood samples were collected from participants. Biochemical data were obtained from existing health records, reflecting results from the previous 3 months, measured after a minimum 8-hour fasting period using standard laboratory methods.
Baseline, Week 8 and 6 months post-intervention
HDL cholesterol (mg/dL)
Prazo: Baseline, Week 8 and 6 months post-intervention
No additional blood samples were collected from participants. Biochemical data were obtained from existing health records, reflecting results from the previous 3 months, measured after a minimum 8-hour fasting period using standard laboratory methods.
Baseline, Week 8 and 6 months post-intervention
LDL cholesterol (mg/dL)
Prazo: Baseline, Week 8 and 6 months post-intervention
No additional blood samples were collected from participants. Biochemical data were obtained from existing health records, reflecting results from the previous 3 months, measured after a minimum 8-hour fasting period using standard laboratory methods.
Baseline, Week 8 and 6 months post-intervention
Thyroid stimulating hormone (TSH) (µIU/mL)
Prazo: Baseline, Week 8 and 6 months post-intervention
No additional blood samples were collected from participants. Biochemical data were obtained from existing health records, reflecting results from the previous 3 months, measured after a minimum 8-hour fasting period using standard laboratory methods.
Baseline, Week 8 and 6 months post-intervention
Alanine aminotransferase (ALT) (U/L)
Prazo: Baseline, Week 8 and 6 months post-intervention
No additional blood samples were collected from participants. Biochemical data were obtained from existing health records, reflecting results from the previous 3 months, measured after a minimum 8-hour fasting period using standard laboratory methods.
Baseline, Week 8 and 6 months post-intervention
Aspartate aminotransferase (AST) (U/L)
Prazo: Baseline, Week 8 and 6 months post-intervention
No additional blood samples were collected from participants. Biochemical data were obtained from existing health records, reflecting results from the previous 3 months, measured after a minimum 8-hour fasting period using standard laboratory methods.
Baseline, Week 8 and 6 months post-intervention

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
perceived stress level
Prazo: Baseline, Week 8 and 6 months post-intervention
Assessed using the Perceived Stress Scale. Scores on the Perceived Stress Scale-14 range from 0 to 56, with a higher score indicating a greater perception of stress (a worse outcome). No cut-off point has been established for the scale.
Baseline, Week 8 and 6 months post-intervention
dietary self-efficacy
Prazo: Baseline, Week 8 and 6 months post-intervention
Assessed using the Dietary Self-Efficacy Scale. Scores on the Dietary Self-Efficacy Scale range from 11 to 55, with a higher score indicating greater dietary self-efficacy (a better outcome). No cut-off point has been established for the scale.
Baseline, Week 8 and 6 months post-intervention
General Well-Being
Prazo: Baseline, Week 8 and 6 months post-intervention
Assessed using the General Well-Being Scale Short Form. Scores on the General Well-being Scale Short Form range from 14 to 70, with a higher score indicating a higher level of well-being (a better outcome). No cut-off point has been established for the scale.
Baseline, Week 8 and 6 months post-intervention

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Diretor de estudo: Elif Dadak Yıldırım, PhD(c), Ankara Medipol University
  • Investigador principal: İlknur G Yıldırım, Asst. Prof., Ankara Medipol University

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

4 de agosto de 2025

Conclusão Primária (Real)

1 de outubro de 2025

Conclusão do estudo (Real)

1 de maio de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

30 de abril de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

8 de maio de 2026

Primeira postagem (Real)

13 de maio de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

13 de maio de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

8 de maio de 2026

Última verificação

1 de abril de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

Individual participant data will not be shared to protect participant privacy and confidentiality. All data were collected under informed consent with assurances of anonymity

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever